Page last updated: 2024-10-28

glyburide and Brain Infarction

glyburide has been researched along with Brain Infarction in 4 studies

Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.

Brain Infarction: Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.

Research Excerpts

Excerpt	Relevance	Reference
"To create HT model, right middle cerebral artery occlusion (MCAO) was conducted with intraluminal thread technique; 30 min after MCAO, 50 microL arterial blood was injected into the caudate nucleus where the infarction occurred."	1.35	Brain damage related to hemorrhagic transformation following cerebral ischemia and the role of K ATP channels. ( Li, LT; Yang, Y; Yin, J; Zhang, XJ, 2008)
"In this study, we determined whether repeated brief isoflurane (Iso) anesthesia induces ischemic tolerance to focal cerebral ischemia in a dose-response manner and whether the effect is dependent on adenosine triphosphate-regulated potassium channels."	1.32	Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. ( Hou, L; Lu, Z; Wu, M; Xiong, L; Zhang, X; Zheng, Y; Zhu, Z, 2003)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Sheth, KN	2
Kimberly, WT	2
Elm, JJ	2
Kent, TA	1
Yoo, AJ	1
Thomalla, G	1
Campbell, B	1
Donnan, GA	1
Davis, SM	1
Albers, GW	1
Jacobson, S	1
del Zoppo, G	1
Simard, JM	1
Stern, BJ	1
Mandava, P	1
Beslow, LA	1
Sze, GK	1
Yang, Y	1
Zhang, XJ	1
Yin, J	1
Li, LT	1
Xiong, L	1
Zheng, Y	1
Wu, M	1
Hou, L	1
Zhu, Z	1
Zhang, X	1
Lu, Z	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
A Multi-Center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.[NCT01268683]			Phase 1/Phase 2	10 participants (Actual)	Interventional	2011-05-26	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in DWI Lesion Volume

(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3 (Day 3 reported)

Intervention	Cm^3 (Mean)
RP-1127 (Glyburide for Injection)	60.30

Number of MRI Assessments Per Participant

(NCT01268683)
Timeframe: Up to Day 3

Intervention	Number of MRIs (Mean)
RP-1127 (Glyburide for Injection)	3.9

Number of Participants Requiring Decompressive Craniectomy (DC)

(NCT01268683)
Timeframe: Up to Day 90

Intervention	Number of Participants (Number)
RP-1127 (Glyburide for Injection)	2

Percentage of Dose Reductions/ Dose Suspensions

(NCT01268683)
Timeframe: Up to Day 3

Intervention	Percentage of Participants (Number)
RP-1127 (Glyburide for Injection)	0

Percentage of Enrolled Participants to Screened Participants

(NCT01268683)
Timeframe: Day 1

Intervention	Percentage of Participants (Number)
RP-1127 (Glyburide for Injection)	5.7

Percentage of Participants Completing 90-Day Follow-Up

(NCT01268683)
Timeframe: Day 90

Intervention	Percentage of Participants (Number)
RP-1127 (Glyburide for Injection)	80

Percentage of Participants Requiring One or More Hypoglycemia Treatments

(NCT01268683)
Timeframe: Up to Day 4

Intervention	Percentage of Participants (Number)
RP-1127 (Glyburide for Injection)	0

Percentage of Participants With All Four MRI Assessments Per Protocol

(NCT01268683)
Timeframe: Up to Day 3

Intervention	Percentage of Participants (Number)
RP-1127 (Glyburide for Injection)	90

Percentage of Participants With Pre-specified Adverse Events Associated With Glyburide According to Protocol

(NCT01268683)
Timeframe: Up to Day 4

Intervention	Percentage of Participants (Number)
RP-1127 (Glyburide for Injection)	0

Rate of Enrollment

The number of months to enroll 10 participants. (NCT01268683)
Timeframe: Day 1

Intervention	Months (Number)
RP-1127 (Glyburide for Injection)	9.6

Absolute Diffusion Weighted Imaging (DWI) Lesion Volume

(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3

Intervention	Cm^3 (Mean)
	Baseline	Day 1	Day 2	Day 3
RP-1127 (Glyburide for Injection)	101.76	141.62	152.31	169.73

Frequency of Hemorrhagic Events

(NCT01268683)
Timeframe: Day 1, Day 2, and Day 3

Intervention	Number of Events (Number)
	Hemorrhagic Infarction Type 1	Hemorrhagic Infarction Type 2	Parenchymal Hematoma Type 1	Parenchymal Hematoma Type 2
RP-1127 (Glyburide for Injection)	3	8	0	0

Full Outline of UnResponsiveness (FOUR) Score

The FOUR Score is a 17-point scale (with potential scores ranging from 0 - 16). Decreasing FOUR Score is associated with worsening level of consciousness. The FOUR Score assesses four domains of neurological function: eye responses, motor responses, brainstem reflexes, and breathing pattern. (NCT01268683)
Timeframe: Baseline, Day 1, Day 2, Day 3, and Day 7

Intervention	Score on a Scale (Mean)
	Baseline	Day 1	Day 2	Day 3	Day 7
RP-1127 (Glyburide for Injection)	15.1	14.5	14.6	14.6	14.8

Glasgow Coma Scale (GCS) Score

The GCS is scored on a scale between 3 and 15 (3 = the worst, and 15 = best). It is composed of three parameters : Best Eye Response (scored on a scale of 1-4), Best Verbal Response (scored on a scale of 1-5), Best Motor Response (scored on a scale of 1-6) (NCT01268683)
Timeframe: Baseline, Day 1, Day 2, Day 3, and Day 7

Intervention	Score on a scale (Mean)
	Baseline	Day 1	Day 2	Day 3	Day 7
RP-1127 (Glyburide for Injection)	12.5	11.9	12.5	12.8	13.5

Infarcted Hemisphere Volume

(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3

Intervention	Centimeters cubed (cm^3) (Mean)
	Baseline	Day 1	Day 2	Day 3
RP-1127 (Glyburide for Injection)	135.20	156.78	165.38	181.71

Ipsilateral Ventricle Volume

(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3

Intervention	Cm^3 (Mean)
	Baseline	Day 1	Day 2	Day 3
RP-1127 (Glyburide for Injection)	11.78	9.25	8.92	10.07

Midline Shift

(NCT01268683)
Timeframe: Baseline, Day 1, Day 2, and Day 3

Intervention	Millimeters (mm) (Mean)
	Baseline	Day 1	Day 2	Day 3
RP-1127 (Glyburide for Injection)	0.56	2.00	2.63	2.50

National Institute of Health Stroke Scale (NIHSS) Score

The NIHSS is composed of 11 categories, each of which is scored between 0 and 4. A score of 0 indicates normal function, a higher score indicates more impairment. Category scores are summed to generate the total NIHSS score (possibles scores range from 0-42). (NCT01268683)
Timeframe: Baseline, Day 1, Day 2, Day 3, and Day 7

Intervention	Score on a Scale (Mean)
	Baseline	Day 1	Day 2	Day 3	Day 7
RP-1127 (Glyburide for Injection)	17.8	18.4	15.6	16.2	13.9

Number of Participants With a Modified Rankin Scale (mRS) Score ≤ 4

The mRS scale runs from 0-6, the scoring is as follows: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead (NCT01268683)
Timeframe: Day 30, Day 90

Intervention	Number of Participants (Number)
	Day 30	Day 90
RP-1127 (Glyburide for Injection)	9	8

Number of Participants With Adverse Events and Serious Adverse Events

Adverse Events (AE's) of special interest (cardiac events, difficulty controlling blood sugar, liver problems, and blood disorders, including anemia) will be followed for 30 days and all Severe Adverse Events (SAE's) will be followed for 90 days. SAE's and AE's were reviewed, and the number of participants with unanticipated adverse events, or drug-related SAE's were assessed. (NCT01268683)
Timeframe: Up to Day 90

Intervention	Number of Participants (Number)
	Adverse Events	Serious Adverse Events
RP-1127 (Glyburide for Injection)	10	3

Trials

1 trial available for glyburide and Brain Infarction

Article	Year
Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocritical care, 2016, Volume: 24, Issue:1 Topics: Adult; Aged; Brain Edema; Brain Infarction; Double-Blind Method; Female; Glyburide; Humans; Hypoglyc	2016

Other Studies

3 other studies available for glyburide and Brain Infarction

Article	Year
Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocritical care, 2014, Volume: 21, Issue:1 Topics: Adult; Aged; Brain Edema; Brain Infarction; Clinical Trials, Phase II as Topic; Diffusion Magnetic R	2014
Brain damage related to hemorrhagic transformation following cerebral ischemia and the role of K ATP channels. Brain research, 2008, Nov-19, Volume: 1241 Topics: Adenosine Triphosphatases; Animals; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Cerebral H	2008
Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. Anesthesia and analgesia, 2003, Volume: 96, Issue:1 Topics: Anesthetics, Inhalation; Animals; ATP-Binding Cassette Transporters; Blood Gas Analysis; Body Temper	2003